Supplementary Text 1

Materials and Methods

List of cell culture reagents.

Cell culture reagents were procured from Gibco Laboratories (Grand Island, NY, USA). ECL western blotting detection reagent was procured from GE Healthcare (Buckinghamshire, UK). Various primary antibodies used in the study were obtained from Cell Signaling Technology (MA, USA). Phorbol 12-myristate 13-acetate (PMA), monodansylcadaverine (MDC, a fluorescent dye that stains autophagic vacuoles), anti-rabbit HRP antibody, Bafilomycin A1 (Baf-A1, a vacuolar ATPase inhibitor), BCA kit, 100 × protease inhibitor cocktail and Fluoromount aqueous mounting medium were procured from Sigma (St. Louis, MO, USA). Middlebrook growth media 7H9 broth, 7H10 agar, 7H11 agar was ordered from BD (MD, USA). WST-1 cell viability assay kit and other general chemicals unless not mentioned were obtained from HiMedia Laboratory (Mumbai, India).

Chemical synthesis and characterization of various pyrazole derivatives General procedure for the synthesis of compounds 3a-f.

For synthesis of the pyrazole derivatives, the commercially available acetylacetone (500 mg, 4.99 mmol) and compound 2a-f (4.99 mmol) were mixed in a round bottom flask containing 5 mL glycerol-water (1:1) mixture as a solvent and heated for 3-4 hrs at 90°C with continuous stirring. The progress of the reaction was monitored by TLC and the reaction mixture was allowed to cool upon completion. The desired final product was extracted multiple times using ethyl acetate. The combined organic layer was washed with water, brine solution, dried by adding anhydrous Na₂SO₄ and the final product was purified by column chromatography.

1-(4-Methoxyphenyl)-3,5-dimethyl-1H-pyrazole (3a): Light yellow oil; Yield: 82%; IR (KBr, cm⁻¹): 2964, 1553, 1514, 1246, 745; ¹H NMR (400 MHz, CDCl₃): δ 2.23 (s, 3H), 2.28 (s, 3H), 3.83 (s, 3H), 5.95 (s, 1H), 6.94 (d, J = 8.70 Hz, 2H), 7.31 (d, J = 8.70 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 12.22, 13.58, 55.60, 106.32, 114.17, 126.46, 133.16, 139.56, 148.60, 158.84; ESI-HRMS (m/z) calculated for C₁₂H₁₄N₂O: 202.1106; observed: 203.2461 (MH)⁺.

3,5-dimethyl-1-phenyl-1H-pyrazole (3b): Light yellow oil; Yield: 80%; IR (KBr, cm⁻¹): 2922, 1596, 1500, 1373, 1025, 753; ¹H NMR (400 MHz, CDCl₃): δ 2.30 (s, 6H), 5.99 (s, 1H), 7.32-7.35 (m, 1H), 7.41-7.46 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 12.46, 13.59, 106.99, 124.84, 127.33, 129.07, 139.48, 139.97, 149.04; ESI-HRMS (m/z) calculated for C₁₁H₁₂N₂: 172.1000; observed: 173.1453 (MH)⁺.

3,5-dimethyl-1-(o-tolyl)-1H-pyrazole (3c): Brown liquid; Yield: 83%; IR (KBr, cm⁻¹): 2923, 1583, 1552, 1287, 1129, 1031, 775; ¹H NMR (400 MHz, CDCl₃): δ 2.05 (s, 6H), 2.29 (s, 3H), 5.96 (s, 1H), 7.22-7.33 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 11.35, 13.66, 17.30, 105.00, 126.50, 128.00, 129.00,

130.89, 136.39, 138.83, 140.29, 148.57; ESI-HRMS (m/z) calculated for $C_{12}H_{14}N_2$: 186.1157; observed: 187.1643 (MH)⁺.

1-(2-Chlorophenyl)-3,5-dimethyl-1H-pyrazole (3d): Light yellow oil; Yield: 82%; IR (KBr, cm⁻¹): 2968, 1556, 1496, 1217, 1032, 745, 660; ¹H NMR (400 MHz, CDCl₃): δ 2.12 (s, 3H), 2.31 (s, 3H), 6.00 (s, 1H), 7.37-7.41 (m, 3H), 7.50-7.53 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 11.32, 13.69, 105.58, 127.61, 130.02, 130.24, 132.60, 137.56, 141.29, 149.36; ESI-HRMS (m/z) calculated for C₁₁H₁₁ClN₂: 206.0611; observed: 207.0686 (MH)⁺, 209.0645 (MH+2)⁺.

1-(3-Chlorophenyl)-3,5-dimethyl-1H-pyrazole (3e): Light yellow oil; Yield: 85%; IR (KBr, cm⁻¹): 2973, 1590, 1556, 1489, 1216, 744, 686; ¹H NMR (400 MHz, CDCl₃): δ 2.28 (s, 3H), 2.32 (s, 3H), 6.00 (s, 1H), 7.29-7.37 (m, 3H), 7.47-7.48 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 12.59, 13.57, 107.64, 122.56, 124.88, 127.29, 130.02, 134.74, 139.57, 141.03, 149.60; ESI-HRMS (m/z) calculated for C₁₁H₁₁ClN₂: 206.0611; observed: 207.0874 (MH)⁺, 209.0732 (MH+2)⁺.

1-(4-Chlorophenyl)-3,5-dimethyl-1H-pyrazole (3f): Light yellow oil; Yield: 75%; IR (KBr, cm⁻¹): 2973, 1554, 1498, 1216, 1037, 744, 665; ¹H NMR (400 MHz, CDCl₃): δ 2.28-2.29 (m, 6H), 5.99 (s, 1H), 7.35-7.42 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 12.48, 13.56, 107.42, 125.87, 129.22, 132.93, 138.41, 139.50, 149.43; ESI-HRMS (m/z) calculated for C₁₁H₁₁ClN₂: 206.0611; observed: 207.0848 (MH)⁺, 209.0719 (MH+2)⁺.

General procedure for the synthesis of compounds 5b-k.

Acetylacetone (500 mg, 4.99 mmol) was mixed in a round bottom flask containing diluted HCl (5 mL) and the mixture was cooled in ice bath to 37°C followed by the addition of NaNO₂ (344.95 mg, 5 mmol, 5 mL H₂O) solution. The reaction mixture was subsequently left undisturbed for 20 mins. Simultaneously, substituted phenyl hydrazine hydrochloride (4.99 mmol) was dissolved in a mixture of polyethylene glycol-water (1:1) solvent system. The solution of substituted phenyl hydrazine hydrochloride was added dropwise to the above reaction mixture with continuous stirring and the temperature of the reaction mixture was slowly allowed to rise to 37°C from room temperature. The obtained green precipitate was filtered, washed with 50% PEG solution, dried and purified by column chromatography using silica gel and ethyl acetate-hexane as a solvent system.

3,5-dimethyl-4-nitroso-1-phenyl-1H-pyrazole (5b): Greenish solid; Yield: 64%; mp 96-98 °C; IR (KBr, cm⁻¹): 2923, 1543, 1511, 1383, 1088, 1016, 766; ¹H NMR (400 MHz, CDCl₃): δ 2.43 (s, 3H), 2.94 (s, 3H), 7.50-7.58 (m, 5H); ¹³C NMR (100 MHz, CDCl₃): δ 11.06, 12.98, 124.99, 129.14, 129.45, 137.61, 160.66; ESI-HRMS (m/z) calculated for C₁₁H₁₁N₃O: 201.0902 ; observed: 202.0976 (MH)⁺.

3,5-dimethyl-4-nitroso-1-(o-tolyl)-1H-pyrazole (5c): Greenish solid; Yield: 66%; mp 68-70 °C; IR (KBr, cm⁻¹): 2929, 1539, 1512, 1338, 1236, 1018, 771; ¹H NMR (400 MHz, CDCl₃): δ 2.14 (s, 3H), 2.45(brs, 3H), 2.66 (brs, 3H), 7.28-7.45 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 10.57, 13.16, 17.44, 127.16, 127.32, 130.42, 131.53, 135.69, 136.44, 160.27; ESI-HRMS (m/z) calculated for C₁₂H₁₃N₃O: 215.1059; observed: 216.1125 (MH)⁺.

1-(2-Chlorophenyl)-3,5-dimethyl-4-nitroso-1H-pyrazole (5d): Greenish solid; Yield: 65%; mp 116-118 °C; IR (KBr, cm⁻¹): 2920, 1546, 1513, 1349, 1225, 1098, 768, 718; ¹H NMR (400 MHz, CDCl₃): δ 2.44(brs, 3H), 2.76 (brs, 3H), 7.48-7.63 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 10.56, 13.20, 128.18, 129.39, 130.71, 131.67, 132.02, 135.31, 160.13; ESI-HRMS (m/z) calculated. for C₁₁H₁₀ClN₃O: 235.0512; observed: 236.0581 (MH)⁺, 238.0557 (MH+2)⁺.

1-(3-Chlorophenyl)-3,5-dimethyl-4-nitroso-1H-pyrazole (5e): Greenish solid; Yield: 69%; mp 87-89 °C; IR (KBr, cm⁻¹): 2922, 1591, 1544, 1350,1222, 1078, 777, 682; ¹H NMR (400 MHz, CDCl₃): δ 2.41 (s, 3H), 2.97 (s, 3H), 7.42-7.43 (m, 1H), 7.49-7.50 (m, 2H), 7.57 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 11.27, 13.09, 123.12, 125.48, 129.46, 130.58, 135.43, 138.86, 160.65; ESI-HRMS (m/z) calculated for C₁₁H₁₀ClN₃O: 235.0512; observed: 236.0606 (MH)⁺, 238.058 (MH+2)⁺.

1-(2-Chlorophenyl)-3,5-dimethyl-4-nitroso-1H-pyrazole (5f) Greenish solid; Yield: 70%; mp 120-122 °C; IR (KBr, cm⁻¹): 2927, 1543, 1508, 1344, 1235, 1085, 827, 769; ¹H NMR (400 MHz, CDCl₃): δ 2.40 (s, 3H), 2.95 (s, 3H), 7.47 (d, J = 8.70 Hz, 2H), 7.54 (d, J = 8.24 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 11.24, 13.10, 126.33, 129.84, 135.26, 136.32, 160.70; ESI-HRMS (m/z) calculated for C₁₁H₁₀ClN₃O: 235.0512; observed: 236.0597 (MH)⁺, 238.0579 (MH+2)⁺.

3,5-dimethyl-4-nitroso-1-(p-tolyl)-1H-pyrazole (5g): Greenish solid; Yield: 67%; mp 114-116 °C; IR (KBr, cm⁻¹): 2926, 1541, 1517, 1342, 1232, 1080, 817; ¹H NMR (400 MHz, CDCl₃): δ 2.41-2.45 (m, 6H), 2.91 (brs, 3H), 7.33-7.39 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 9.02, 10.95, 19.12, 122.82, 127.98, 133.09, 137.38, 158.58; ESI-HRMS (m/z) calculated for C₁₂H₁₃N₃O: 215.1059; observed: 216.2504 (MH)⁺.

1-(4-Bromophenyl)-3,5-dimethyl-4-nitroso-1H-pyrazole (5h): Greenish solid; Yield: 62%; mp 118-120 °C; IR (KBr, cm⁻¹): 2925, 1543, 1508, 1348, 1228, 1072, 769, 705; ¹H NMR (400 MHz, CDCl₃): δ 2.40 (brs, 3H), 2.96 (brs, 3H), 7.41 (d, J = 8.24 Hz, 2H), 7.70 (d, J = 8.70 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 11.26, 13.11, 123.25, 126.57, 132.82, 136.83, 160.71; ESI-HRMS (m/z) calculated for $C_{11}H_{10}BrN_3O$: 279.0007; observed: 280.0074 (MH)⁺, 282.0058 (MH+2)⁺.

4-(3,5-dimethyl-4-nitroso-1H-pyrazol-1-yl)benzonitrile (5i): Greenish solid; Yield: 65%; mp 126-128 °C; IR (KBr, cm⁻¹): 2932, 2227, 1544, 1510, 1336, 1230, 839, 771; ¹H NMR (400 MHz, CDCl₃): δ 2.39 (s, 3H), 3.06 (s, 3H), 7.73 (d, J = 8.24 Hz, 2H), 7.87 (d, J = 8.24, Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 11.51, 13.14, 112.80, 117.78, 125.28, 133.59, 141.46, 160.62; ESI-HRMS (m/z) calculated for C₁₂H₁₀N₄O: 226.0855; observed: 227.0936 (MH)⁺.

1-(3,4-dimethylphenyl)-3,5-dimethyl-4-nitroso-1H-pyrazole (5j): Greenish solid; Yield: 65%; mp 106-108 °C; IR (KBr, cm⁻¹): 2922, 1541, 1514, 1323, 1172, 1043, 790; ¹H NMR (400 MHz, CDCl₃): δ 2.31-2.42 (m, 9H), 2.90 (brs, 3H), 7.19 (d, J = 7.79 Hz, 1H), 7.27-7.30 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 11.01, 12.93, 19.46, 19.75, 122.15, 125.93, 126.03, 130.31, 135.26, 138.02, 138.16, 160.66; ESI-HRMS (m/z) calculated for C₁₃H₁₅N₃O: 229.1215; observed: 230.1285 (MH)⁺.

1-(2,5-dichlorophenyl)-3,5-dimethyl-4-nitroso-1H-pyrazole (5k): Greenish solid; Yield: 67%; mp 98-100 °C; IR (KBr, cm⁻¹): 2926, 1541, 1465, 1344, 1255, 1095, 817, 777; ¹H NMR (400 MHz, CDCl₃):

δ 2.44 (s, 3H), 2.77 (s, 3H), 7.49-7.57 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 10.58, 13.13, 129.66, 130.42, 131.50, 131.80, 133.82, 136.16, 159.93; ESI-HRMS (m/z) calculated for C₁₁H₉Cl₂N₃O: 269.0123; observed: 270.0339 (MH)⁺, 272.0264 (MH+2)⁺, 274.0155(MH+4)⁺.

Procedure for the synthesis of 3,5-dimethyl-1-phenyl-1H-pyrazol-4-amine (6).

Compound 3,5-dimethyl-4-nitroso-1-phenyl-1*H*-pyrazole (500 mg, 2.48 mmol) was dissolved in methanol (5 mL) and hydrogen gas was passed in the presence of Pd/C (50 mg) at 60 psi pressure followed by shaking for 3-4 hrs at room temperature. The completion of reaction was determined by TLC, palladium was removed by filtering through celite pad and followed by washing with methanol. The filtrate obtained was combined and dried using rotavapor at reduced pressure. Subsequently, 50 mL diluted HCL was added to the crude product with stirring. The impurities were removed by the addition of ethyl acetate, the-aqueous layer containing final product was neutralised with saturated K_2CO_3 solution and finally isolated by extraction with ethyl acetate.

3,5-dimethyl-1-phenyl-1H-pyrazol-4-amine (6): Yellow solid; Yield: 85%; mp 64-66 °C 67 °C; IR (KBr, cm⁻¹): 3323, 2921, 1598, 1438, 1368, 1215, 1074, 766; ¹H NMR (400 MHz, CDCl₃): δ 2.20 (s, 3H), 2.22 (s, 3H), 2.57 (brs, 2H), 7.24-7.42 (m, 5H); ¹³C NMR (100 MHz, CDCl₃): δ 10.41, 11.00, 124.20, 124.94, 126.81, 127.14, 129.08, 140.28, 140.98; ESI-HRMS (m/z) calculated for C₁₁H₁₃N₃: 187.1109; observed: 188.1328 (MH)⁺.

Procedure for the synthesis of 4-bromo/chloro-3,5-dimethyl-1-phenyl-1H-pyrazole (7a-b).

The synthesized compound 3,5-dimethyl-1-phenyl-1*H*-pyrazole (300 mg, 1.74 mmol) and N-halo-succinimide (1.74 mmol) were taken in a round bottom flask containing 5 mL of water. The reaction mixture containing N-bromosuccinimide or N-chlorosuccinimide was stirred at room temperature or at 37 °C, respectively for 2 hrs. The completion of reaction was confirmed by TLC and the product was extracted with ethyl acetate multiple times. The combined organic layer was washed with water and brine, dried by the addition of Na₂SO₄ and ethyl acetate to purify the desired products. *4-Bromo-3,5-dimethyl-1-phenyl-1H-pyrazole (7a)*: Yellow oil; Yield: 75%; IR (KBr, cm⁻¹): 2982, 1597, 1502, 1373, 1216, 1080, 744, 691; ¹H NMR (400 MHz, CDCl₃): δ 2.30 (s, 6H), 7.38-7.41 (m, 3H), 7.45-7.47 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 11.69, 12.29, 96.07, 124.60, 127.75, 129.10, 137.44, 139.70, 147.50; ESI-HRMS (m/z) calculated for C₁₁H₁₁BrN₂: 250.0106; observed: 251.0179 (MH)⁺, 253.0159 (MH+2)⁺.

4-Chloro-3,5-dimethyl-1-phenyl-1H-pyrazole (7*b*): Yellow oil; Yield: 75%; IR (KBr, cm⁻¹): 2923, 1596, 1501, 1374, 1272, 1099, 760, 692; ¹H NMR (400 MHz, CDCl₃): δ 2.30 (s, 6H), 7.37-7.46 (m, 5H); ¹³C NMR (100 MHz, CDCl₃): δ 10.91, 11.49, 109.89, 124.62, 127.81, 129.26, 135.79, 139.82, 146.14; ESI-HRMS (m/z) calculated for C₁₁H₁₁ClN₂: 206.0611; observed: 207.0930 (MH)⁺, 209.0757 (MH+2)⁺.



Characterization details of various scaffolds prepared in the present study.





































LEGENDS FOR SUPPLEMENTARY FIGURES

Supplementary Figure 1: This figure shows the chemical structures of shortlisted compounds obtained from phenotypic screens performed in *M. bovis* BCG.

Supplementary Figure 2: Two drug checkerboard assay to study the interaction of NSC 18725 with INH, RIF, EMB, BDQ, BTZ043 or PA-824. Fractional inhibitory concentrations (FICs) and fractional inhibitory concentration index (\sum FIC) for various drug combinations were calculated using the following formula: FIC=MIC in combination/MIC alone. \sum FIC = FIC of drug A + FIC of drug B. \sum FIC value ≤ 0.5 indicate synergistic activity, \sum FIC of ≥ 4.0 indicate antagonistic activity, and values in between (≤ 4.0 and > .5) indicate an additive interaction. Wells showing + sign denote growth, - sign denote no growth, and (-) sign denote activity due to a combination. The data shown in this panel is representative of three independent experiments.